Hypofractionated Stereotactic Body Radiation Therapy (SBRT)

Inclusion Criteria:

18 years of age or older
Histologically confirmed diagnosis of adenocarcinoma of the prostate within 180 days of enrollment
Signed informed consent
Gleason score ≤ 7
If Gleason 7 (3+4=7 or 4+3=7) then <50% of biopsy cores must be positive for any pathologic grade of prostate cancer
If Gleason score <7 then there is no limit on the percentage of biopsy cores involved by prostate cancer
PSA (within 90 days prior to enrollment)
≤ 15 ng/ml prior to start of therapy if Gleason ≤ 6 and
≤ 10 ng/ml prior to start of therapy if Gleason 7
No plan to use hormone therapy prior to evidence of biochemical failure(ie: No neoadjuvant or adjuvant ADT)
Tumor stage: T1a, T1b, T1c, T2a, T2b
ECOG Performance Status 0-1

Exclusion Criteria:

A history of other malignancy diagnosed within the previous 60 months except for non-melanoma skin cancer.
Any patients who have received other investigational therapy within the last 60 days
Individuals that have previously been implanted with permanent Beacon transponders
Patients that have any prosthetic implants in the pelvic region that contain metal or conductive materials (e.g., an artificial hip)
Patients with implanted pacemaker or defibrillators
Patients who are felt to have body habitus not conducive to tracking with Calypso beacons
Positive lymph nodes or metastatic disease from prostate cancer
Tumor stage: T2c, T3, or T4
Previous pelvic radiation therapy
Previous surgery or chemotherapy for prostate cancer
Previous transuretheral resection of the prostate (TURP) or cryotherapy to the prostate
Prior hormone therapy or plans for concurrent or post treatment adjuvant hormonal therapy or chemotherapy
Hormone therapy to include LHRH agonist or oral anti-androgen
Finasteride and Dutasteride use not excluded
Concomitant antineoplastic therapy (including surgery, cryotherapy, conventionally fractionated radiation therapy, and chemotherapy) while on this protocol
History of Crohn's Disease or Ulcerative Colitis